SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $37,600.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $7.52, for a total transaction of $37,600.00. Following the completion of the sale, the insider directly owned 218,387 shares in the company, valued at approximately $1,642,270.24. This trade represents a 2.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.16, for a total transaction of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $7.50 on Monday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The firm has a fifty day moving average price of $5.89 and a 200 day moving average price of $5.22. The company has a market cap of $629.17 million, a P/E ratio of -6.52 and a beta of 0.96. SOPHiA GENETICS SA has a 12 month low of $3.10 and a 12 month high of $7.88.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Sell-side analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SOPH has been the topic of several research analyst reports. HC Wainwright raised their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Finally, BTIG Research raised their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS currently has an average rating of “Hold” and a consensus price target of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after buying an additional 5,432,871 shares during the period. AWM Investment Company Inc. purchased a new position in SOPHiA GENETICS during the 2nd quarter worth $9,809,000. Akre Capital Management LLC lifted its stake in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after acquiring an additional 1,481,636 shares during the period. Hodges Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS in the 1st quarter worth $2,157,000. Finally, Royce & Associates LP purchased a new stake in shares of SOPHiA GENETICS in the fourth quarter valued at about $2,009,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.